Characteristics and clinical outcomes of patients with severe asthma receiving tezepelumab after marketing approval in Spain (T-ROSS II study): an observational study protocol

Christian Domingo, Gema Monteagudo, Francisco Ramos-Lima, Marta Alegría, Gabriel Niza, Marta Robles, Javier Domínguez-Ortega

Open source

DOI
10.1136/bmjopen-2025-115512
Published
2026-06
Container
BMJ Open
Publisher
BMJ
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2025-115512,
  title = {Characteristics and clinical outcomes of patients with severe asthma receiving tezepelumab after marketing approval in Spain (T-ROSS II study): an observational study protocol},
  author = {Christian Domingo and Gema Monteagudo and Francisco Ramos-Lima and Marta Alegría and Gabriel Niza and Marta Robles and Javier Domínguez-Ortega},
  year = {2026},
  journal = {BMJ Open},
  doi = {10.1136/bmjopen-2025-115512},
  url = {https://doi.org/10.1136/bmjopen-2025-115512}
}

RIS

TY  - JOUR
TI  - Characteristics and clinical outcomes of patients with severe asthma receiving tezepelumab after marketing approval in Spain (T-ROSS II study): an observational study protocol
AU  - Christian Domingo
AU  - Gema Monteagudo
AU  - Francisco Ramos-Lima
AU  - Marta Alegría
AU  - Gabriel Niza
AU  - Marta Robles
AU  - Javier Domínguez-Ortega
PY  - 2026
JO  - BMJ Open
DO  - 10.1136/bmjopen-2025-115512
UR  - https://doi.org/10.1136/bmjopen-2025-115512
ER  - 

APA

Domingo, C., Monteagudo, G., Ramos-Lima, F., Alegría, M., Niza, G., Robles, M., & Domínguez-Ortega, J. (2026). Characteristics and clinical outcomes of patients with severe asthma receiving tezepelumab after marketing approval in Spain (T-ROSS II study): an observational study protocol. BMJ Open. https://doi.org/10.1136/bmjopen-2025-115512

Source records